Allan Reine - Jan 16, 2024 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)

Role
Chief Financial Officer
Signature
/s /Adrian Gottschalk, Attorney-in-Fact for Allan Reine
Stock symbol
FHTX
Transactions as of
Jan 16, 2024
Transactions value $
$0
Form type
4
Date filed
1/17/2024, 04:01 PM
Previous filing
Jan 30, 2023
Next filing
Jan 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding FHTX Common Stock 53.8K Jan 16, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding FHTX Stock Options (Right to buy) 258K Jan 16, 2024 Common Stock 258K $3.72 Direct F1
holding FHTX Stock Option (right to buy) 91.9K Jan 16, 2024 Common Stock 91.9K $8.77 Direct F2
holding FHTX Stock Option (right to buy) 120K Jan 16, 2024 Common Stock 120K $16.63 Direct F3
holding FHTX Stock Option (right to buy) 135K Jan 16, 2024 Common Stock 135K $14.87 Direct F4
holding FHTX Stock Option (right to buy) 90K Jan 16, 2024 Common Stock 90K $8.38 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Allan Reine is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The option vested as to 25% of the underlying shares of common stock on September 17, 2020, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F2 The option vested as to 25% of the underlying shares of common stock on August 18, 2021, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F3 The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F4 The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F5 The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.

Remarks:

Exit Form 4 filed solely to report the Reporting Person is no longer an officer of the Issuer within the meaning of Rule 16a-1 of the Securities Exchange Act of 1934, as amended.